Intercept Pharmaceuticals has voluntarily withdrawn Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC) from the US market. The decision follows a request from the FDA.
Medical News Today: What is the difference between sclerosing cholangitis and primary biliary cirrhosis?
Sclerosing cholangitis and primary biliary cirrhosis, which is now called primary biliary cholangitis (PBC), are chronic cholestatic liver diseases, but they differ in their causes, affected bile ...
USA Today: 4 ways to embrace life after a primary biliary cholangitis diagnosis
A primary biliary cholangitis (PBC) diagnosis can be life-changing. For many, it’s an emotional journey filled with questions, uncertainties and a need to redefine what life looks like with a chronic ...
Business Wire: Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis
Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis
Healio: Linerixibat lands FDA first for cholestatic pruritus in primary biliary cholangitis
Please provide your email address to receive an email when new articles are posted on . The approval marks the first therapy for cholestatic pruritus in primary biliary cholangitis. Patients assigned ...
MedPage Today: BMI and Autoimmune Liver Disease: Weight Management May Prevent Primary Biliary Cholangitis
—A recent study provides genetic evidence linking a higher body mass index (BMI) to an increased risk of primary biliary cholangitis and autoimmune hepatitis but a decreased risk of primary sclerosing ...
BMI and Autoimmune Liver Disease: Weight Management May Prevent Primary Biliary Cholangitis
—A large international cohort study of patients with primary biliary cholangitis recently demonstrated that the most recent liver stiffness measurement is the single strongest, independent predictor ...